MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)
Portfolio Pulse from
MannKind Corporation has announced six-month results from its Phase 3 INHALE-1 pediatric diabetes trial using inhaled insulin, Afrezza®. The company plans to meet with the FDA for a potential sNDA submission in the first half of 2025. A call is scheduled to discuss the diabetes program's progress.
December 16, 2024 | 11:30 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MannKind Corporation reported positive six-month results from its Phase 3 INHALE-1 trial for Afrezza®, an inhaled insulin for pediatric diabetes. The company plans to meet with the FDA for a potential sNDA submission in the first half of 2025.
The positive trial results and the plan to meet with the FDA for a potential sNDA submission are likely to boost investor confidence in MannKind's product pipeline, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100